ICH GCP E6(R2) vs E6(R3): Key Changes

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-27

Quick Answer

• ICH GCP E6(R3) shifts the focus from procedural compliance toward a quality-driven, risk-based approach that emphasizes critical data and processes over exhaustive documentation.
• Clinical research professionals should update their SOPs, training materials, and monitoring strategies to align with the new principles-based framework while maintaining the foundational protections established in E6(R2).
• The transition does not eliminate the need for source documentation, informed consent, or ethics committee oversight, and sponsors and sites must still comply with local regulatory requirements that may not yet reflect the R3 guidance.

Understanding the Regulatory Context of ICH GCP E6(R2) and E6(R3)

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) maintains the Good Clinical Practice (GCP) guideline as the international ethical and scientific quality standard for designing, conducting, recording, and reporting trials that involve human participants. The E6(R2) addendum, adopted in 2016, introduced risk-based approaches and emphasized quality management, while the E6(R3) principles, released in draft form in 2023 and finalized in January 2025, represent a more substantial restructuring of the guideline.

E6(R3) reorganizes the guideline into two parts. The first part contains the core principles that apply to all trials, while the second part provides detailed guidance that is intended to be more flexible and adaptable to a wider range of trial designs, including decentralized and pragmatic trials. This structural change reflects a deliberate move away from prescriptive requirements toward a framework that allows sponsors and sites to tailor their approaches based on the specific risks and complexities of each trial.

For clinical research professionals, the practical consequence is that the transition requires a shift in mindset. Under E6(R2), compliance was often demonstrated through adherence to detailed procedural requirements. Under E6(R3), the emphasis is on demonstrating that the quality management system is proportionate to the risks of the trial and that critical processes and data are protected. This does not mean that documentation becomes optional, but it does mean that the rationale for documentation and oversight should be tied to the criticality of the data and the risks to participant safety and data integrity.

The U.S. Food and Drug Administration (FDA) has indicated its intention to implement E6(R3) once the guideline is finalized, but the timeline for formal adoption and the specific expectations for sponsors and sites remain subject to regulatory processes. Clinical research professionals should monitor FDA guidance and announcements to understand when and how the new principles will be enforced in the United States.

Core Principles of ICH GCP E6(R3)

The E6(R3) guideline is built on a set of principles that are intended to be universally applicable across trial types and settings. These principles emphasize the protection of trial participants, the reliability of trial results, and the importance of a quality culture that is embedded throughout the trial lifecycle.

One of the central principles is that the rights, safety, dignity, and well-being of trial participants must be protected and should prevail over all other interests. This principle is not new, but E6(R3) articulates it in a way that reinforces the ethical foundation of clinical research. The guideline also emphasizes that trials should be conducted in accordance with the principles of the Declaration of Helsinki and applicable regulatory requirements.

Another key principle is that the quality of a trial should be built into the scientific and operational design from the outset. This means that sponsors and sites should identify the data that are critical to the reliability of the trial results and the processes that are essential to protecting participants. The quality management approach should be proportionate to the risks, meaning that more intensive oversight and documentation should be applied to areas where the risk of error or harm is highest.

E6(R3) also emphasizes the importance of a quality culture that extends beyond the clinical operations team. Senior management, investigators, and all personnel involved in the trial should understand their roles and responsibilities in maintaining quality. This includes a commitment to continuous improvement and a willingness to learn from errors and near misses.

The principles in E6(R3) are intended to be flexible enough to accommodate a wide range of trial designs, including those that use digital health technologies, real-world data, and decentralized elements. This flexibility is a significant departure from the more prescriptive approach of E6(R2), and it places a greater burden on sponsors and sites to justify their choices and document their decision-making.

At a Glance: Key Differences Between E6(R2) and E6(R3)

Practical Implications for Clinical Research Coordinators

Clinical research coordinators (CRCs) are often the primary point of contact for trial participants and are responsible for the day-to-day management of study activities at the site. The transition from E6(R2) to E6(R3) has several practical implications for this role.

Under E6(R3), CRCs should expect to spend more time on risk assessment and less time on routine documentation that does not contribute to participant safety or data integrity. This means that CRCs need to understand which data points in their studies are considered critical and why. For example, the primary efficacy endpoint and the safety data that inform the risk-benefit profile of the investigational product are typically critical, while some secondary data points may be less so. The CRC should be able to articulate the rationale for the level of source documentation and verification applied to each data element.

The principles-based approach of E6(R3) also places a greater emphasis on the CRC's role in identifying and reporting quality issues. CRCs should be encouraged to speak up when they observe deviations from the protocol or when they identify risks that were not anticipated during the design phase. This requires a culture of psychological safety where site staff feel comfortable raising concerns without fear of retribution.

Training under E6(R3) is expected to be more targeted and role-specific. Instead of generic GCP training that covers all aspects of the guideline, CRCs should receive training that is tailored to their specific responsibilities and to the critical processes of the trials they support. This may include training on new technologies, such as electronic patient-reported outcome tools or remote monitoring platforms, that are increasingly used in decentralized trials.

CRCs should also be prepared to work more closely with monitors and other sponsor representatives in a collaborative approach to quality management. Under E6(R3), monitoring is expected to be risk-based and may involve a combination of on-site and remote activities. The CRC should be familiar with the monitoring plan for each study and understand what triggers additional monitoring visits or data verification.

Practical Implications for Clinical Research Associates

Clinical research associates (CRAs), also known as monitors, are responsible for overseeing the conduct of trials at sites and ensuring that the data are accurate, complete, and verifiable. The shift to E6(R3) has significant implications for how CRAs perform their duties.

The most notable change is the move away from routine source data verification (SDV) toward a more targeted approach that focuses on critical data and processes. Under E6(R2), CRAs often performed SDV on a high percentage of data points, sometimes approaching 100 percent for key endpoints. Under E6(R3), the expectation is that SDV will be applied selectively based on the risk assessment and the criticality of the data. This means that CRAs need to be skilled in risk assessment and able to justify their monitoring decisions.

CRAs should also expect to use a wider range of monitoring techniques under E6(R3). In addition to traditional on-site monitoring visits, CRAs may conduct remote monitoring, centralized monitoring, and data analytics to identify trends and outliers. This requires proficiency with electronic data capture systems, clinical trial management systems, and data visualization tools.

The role of the CRA in supporting site quality is also emphasized under E6(R3). Instead of being viewed primarily as an inspector, the CRA is expected to be a partner in quality management, helping sites to identify risks and implement corrective actions. This requires strong communication and problem-solving skills, as well as a deep understanding of the protocol and the investigational product.

CRAs should also be prepared to document their monitoring activities in a way that demonstrates the rationale for their decisions. Under E6(R3), the monitoring report should not simply list the activities performed but should explain why those activities were appropriate given the risks and the criticality of the data. This requires a higher level of analytical thinking and documentation skill than was typically expected under E6(R2).

Risk-Based Quality Management in Practice

Risk-based quality management (RBQM) is a central concept in E6(R3) and represents a significant evolution from the approach described in E6(R2). RBQM is a systematic process that involves identifying, assessing, and controlling risks to the quality of a trial, with the goal of ensuring that the trial results are reliable and that participants are protected.

The first step in RBQM is the identification of critical data and critical processes. Critical data are those data points that are essential to the conclusions of the trial, such as the primary endpoint, key safety endpoints, and data that inform the dosing or randomization of participants. Critical processes are those processes that, if they fail, would have a significant impact on participant safety or data integrity, such as the informed consent process, the randomization and blinding procedures, and the adverse event reporting process.

Once the critical data and processes have been identified, the sponsor and site should assess the risks associated with each one. This assessment should consider the likelihood of an error or failure occurring and the impact that such an error or failure would have on participant safety or the reliability of the trial results. The risk assessment should be documented and should be updated throughout the trial as new information becomes available.

Based on the risk assessment, the sponsor should develop a quality management plan that describes the controls that will be implemented to mitigate the identified risks. These controls may include training, standard operating procedures, monitoring activities, data checks, and audit programs. The level of control should be proportionate to the risk, meaning that higher-risk areas should receive more intensive oversight.

For sites, the practical implication of RBQM is that they should expect to participate in risk assessments and to provide input on the feasibility of the planned controls. Sites should also be prepared to implement quality indicators and to monitor their own performance against these indicators. This may involve tracking metrics such as the number of protocol deviations, the timeliness of data entry, and the completeness of source documentation.

The following flowchart illustrates the risk-based quality management process as described in E6(R3):

flowchart TD
    A[Identify Critical Data and Processes] --> B[Assess Risks]
    B --> C[Develop Quality Management Plan]
    C --> D[Implement Controls]
    D --> E[Monitor and Measure Quality]
    E --> F{New Risks Identified?}
    F -->|Yes| B
    F -->|No| G[Continuous Improvement]
    G --> E

Updating Standard Operating Procedures and Training

The transition from E6(R2) to E6(R3) requires sponsors and sites to update their standard operating procedures (SOPs) and training programs to reflect the new principles-based approach. This is not a simple administrative task, but rather a substantive change that requires careful planning and execution.

The first step in updating SOPs is to conduct a gap analysis that compares the current SOPs against the requirements and principles of E6(R3). This analysis should identify areas where the current procedures are overly prescriptive and may need to be revised to allow for more flexibility, as well as areas where new procedures are needed to address the risk-based approach.

For example, the monitoring SOP should be revised to describe the risk-based monitoring approach, including the criteria for determining the level of source data verification and the use of remote monitoring techniques. The quality management SOP should be revised to describe the process for identifying critical data and processes, conducting risk assessments, and developing quality management plans. The training SOP should be revised to describe the approach for role-specific training and the documentation of training competencies.

Once the SOPs have been updated, the training program should be revised to ensure that all personnel understand the new expectations. Training should be provided to all staff involved in clinical trials, including investigators, coordinators, monitors, data managers, and quality assurance personnel. The training should be tailored to the specific roles and responsibilities of each group and should include practical examples and case studies that illustrate the application of the principles.

The transition to E6(R3) does not happen overnight. Sponsors and sites should develop a transition plan that includes a timeline for updating SOPs, training staff, and implementing the new approach. The transition plan should also include a communication strategy to ensure that all stakeholders are aware of the changes and understand their responsibilities.

Documentation and Record-Keeping Under E6(R3)

Documentation remains a fundamental component of good clinical practice, but the approach to documentation under E6(R3) is more nuanced than under E6(R2). The guideline emphasizes that documentation should be proportionate to the risks and the criticality of the data, instead of being exhaustive for its own sake.

This means that sponsors and sites should be able to justify the level of documentation they maintain for each aspect of the trial. For critical data and processes, detailed documentation is expected, including source documents, protocol deviations, and corrective and preventive actions. For less critical aspects, the documentation may be less detailed, but it should still be sufficient to demonstrate that the trial was conducted in accordance with the protocol and applicable regulations.

The principles-based approach also places a greater emphasis on the quality of documentation instead of the quantity. Documentation should be accurate, legible, contemporaneous, original, and attributable. These principles, often referred to as ALCOA, are not new, but they are reinforced in E6(R3) as the foundation of reliable data.

For electronic records, E6(R3) emphasizes the importance of data integrity and the need for systems that are validated, secure, and auditable. This includes the use of electronic signatures, audit trails, and access controls to ensure that data cannot be altered or deleted without detection. Sponsors and sites should ensure that their electronic systems are compliant with applicable regulations, such as 21 CFR Part 11 in the United States.

The transition to E6(R3) also has implications for the retention of records. The guideline requires that essential documents be retained for a period that is consistent with applicable regulatory requirements, which is typically at least two years after the last approval of a marketing application or, if no application is filed, at least two years after the trial is terminated or completed. Sponsors and sites should ensure that their record retention policies are updated to reflect any changes in the guideline.

Common Failure Patterns in the Transition to E6(R3)

The transition from E6(R2) to E6(R3) presents several challenges that can lead to common failure patterns if not managed carefully. Understanding these patterns can help sponsors and sites avoid them.

One common failure is the assumption that E6(R3) means less documentation and less oversight. While the guideline does emphasize proportionality, it does not reduce the fundamental requirements for protecting participants and ensuring data integrity. Sites that reduce their documentation without a clear rationale may find themselves out of compliance during an audit or inspection.

Another common failure is the lack of a structured approach to risk assessment. Some sponsors may implement risk-based monitoring without first conducting a thorough risk assessment or without updating the risk assessment as the trial progresses. This can lead to monitoring activities that are not aligned with the actual risks of the trial, resulting in either excessive oversight of low-risk areas or insufficient oversight of high-risk areas.

A third common failure is the failure to update training programs. Personnel may continue to operate under the assumptions of E6(R2) even after the SOPs have been updated, leading to inconsistencies in practice. This is particularly common when training is provided as a one-time event instead of as an ongoing process that is reinforced through regular communication and refresher sessions.

A fourth common failure is the lack of collaboration between sponsors and sites. The principles-based approach of E6(R3) requires a partnership between sponsors and sites, but some sponsors may continue to operate in a hierarchical manner, making decisions without input from the sites. This can lead to quality management plans that are not feasible in practice and to a lack of buy-in from site staff.

Finally, a common failure is the failure to document the rationale for decisions. Under E6(R3), the emphasis is on demonstrating that decisions were made based on a thoughtful assessment of risks and criticality. If the rationale is not documented, it may be difficult to defend the decisions during an audit or inspection.

Career Implications for Clinical Research Professionals

The transition to E6(R3) has implications for the careers of clinical research professionals, including those who are just entering the field and those who are seeking to advance their careers. Understanding these implications can help professionals position themselves for success.

For those who are new to the field, the principles-based approach of E6(R3) means that employers are likely to place a greater emphasis on critical thinking and problem-solving skills, in addition to technical knowledge. Candidates who can demonstrate an understanding of risk-based quality management and who can articulate how they would apply the principles in practice may have a competitive advantage.

The U.S. Bureau of Labor Statistics provides information on the education and training pathways for various occupations in the life sciences, including medical scientists and clinical research professionals. According to the Occupational Outlook Handbook, medical scientists typically need a doctoral degree, but there are also opportunities for those with master's degrees in related fields. Clinical research coordinators and clinical research associates may enter the field with a bachelor's degree and gain experience through on-the-job training and certification programs.

The National Institutes of Health offers training and professional development resources for individuals interested in research careers. These resources can be valuable for clinical research professionals who are seeking to deepen their understanding of the regulatory landscape and to develop the skills needed to succeed under E6(R3).

For those who are already in the field, the transition to E6(R3) may require additional training and professional development. Professionals who are proficient in risk assessment, data analytics, and the use of digital health technologies are likely to be in high demand. The American Society for Microbiology and other professional organizations offer career resources and networking opportunities that can help professionals stay current with the latest developments in the field.

The Association of American Veterinary Medical Colleges provides career resources for those interested in veterinary medicine, which may be relevant for professionals who work in veterinary clinical trials or who are considering a transition to this area. While the ICH GCP guideline is primarily focused on human clinical trials, the principles of quality management and risk-based approaches are applicable across research settings.

Observations and Measurements for Assessing Readiness

Sponsors and sites should assess their readiness for the transition to E6(R3) by measuring their current practices against the principles of the new guideline. This assessment should be conducted systematically and should involve input from all relevant stakeholders.

One useful approach is to conduct a self-assessment using a checklist that covers the key areas of the guideline. The checklist should include questions about the identification of critical data and processes, the conduct of risk assessments, the development of quality management plans, the implementation of monitoring activities, the documentation practices, and the training of personnel.

For each question, the site or sponsor should rate its current level of compliance and identify any gaps that need to be addressed. The results of the self-assessment should be documented and used to develop an action plan for the transition.

In addition to the self-assessment, sponsors and sites should consider conducting a mock inspection or audit to test their readiness. This can be done internally or with the assistance of an external consultant. The mock inspection should focus on the areas that are most likely to be scrutinized during a regulatory inspection, such as the quality management plan, the monitoring activities, and the documentation practices.

Sponsors and sites should also track key performance indicators related to quality, such as the number of protocol deviations, the timeliness of data entry, the completeness of source documentation, and the number of corrective and preventive actions. These indicators can provide a baseline for measuring improvement over time and can help to identify areas where additional attention is needed.

Welfare and Safety Context

The transition to E6(R3) does not change the fundamental ethical and safety obligations of clinical research. The protection of trial participants remains the highest priority, and all decisions about trial design, conduct, and oversight should be made with this priority in mind.

The principles-based approach of E6(R3) is intended to enhance participant safety by focusing oversight on the areas where the risk of harm is highest. By identifying critical processes and data, sponsors and sites can allocate their resources more effectively and ensure that the most important aspects of the trial receive the appropriate level of attention.

However, the flexibility of E6(R3) also places a greater burden on sponsors and sites to justify their decisions. This means that the rationale for the level of oversight applied to each aspect of the trial should be documented and should be defensible during an audit or inspection.

Clinical research professionals should also be aware of the ethical considerations that are specific to the populations being studied. For example, trials that involve vulnerable populations, such as children, pregnant women, or individuals with cognitive impairments, may require additional safeguards and oversight. The principles of E6(R3) are intended to be applied in a way that is sensitive to these considerations.

Professional Escalation Criteria

Clinical research professionals should know when to escalate concerns to a higher authority, such as a supervisor, the institutional review board, or the sponsor. The following criteria are intended to provide guidance on when escalation is appropriate.

Escalation is appropriate when there is a risk of serious harm to a trial participant. This includes situations where a participant experiences an adverse event that is unexpected, serious, or life-threatening, or where there is a concern that the investigational product is not safe. In these situations, the immediate priority is to ensure that the participant receives appropriate medical care and that the appropriate authorities are notified.

Escalation is also appropriate when there is a risk of significant data integrity issues. This includes situations where data have been falsified, fabricated, or altered, or where there is a concern that the data cannot be verified. In these situations, the integrity of the trial results is at stake, and the issue should be escalated to the sponsor and, if necessary, to the regulatory authorities.

Escalation is appropriate when there is a significant deviation from the protocol or from applicable regulations. This includes situations where the protocol has been violated in a way that could affect participant safety or the reliability of the trial results. The deviation should be documented and reported in accordance with the applicable requirements.

Finally, escalation is appropriate when there is a concern that the quality management system is not functioning effectively. This includes situations where risks have been identified but not addressed, where corrective and preventive actions have not been implemented, or where there is a pattern of recurring errors. In these situations, the issue should be escalated to senior management to ensure that the necessary resources are allocated to address the problem.

Frequently Asked Questions

What is the main difference between ICH GCP E6(R2) and E6(R3)?

The main difference is the shift from a procedural and prescriptive approach to a principles-based and risk-proportionate approach. E6(R3) emphasizes the identification of critical data and processes, the conduct of risk assessments, and the allocation of oversight resources based on the level of risk. This allows for greater flexibility in trial design and conduct, including the use of decentralized and technology-enabled trials.

When will ICH GCP E6(R3) be implemented in the United States?

The ICH E6(R3) guideline was finalized in January 2025. The U.S. Food and Drug Administration has indicated its intention to implement the guideline, but the timeline for formal adoption and the specific expectations for sponsors and sites remain subject to regulatory processes. Clinical research professionals should monitor FDA guidance and announcements for updates.

Do I need to update my standard operating procedures for E6(R3)?

Yes, sponsors and sites should update their standard operating procedures to reflect the principles and requirements of E6(R3). This includes revising monitoring procedures to describe the risk-based approach, updating quality management procedures to describe the process for identifying critical data and processes, and updating training procedures to describe the approach for role-specific training.

Will E6(R3) reduce the amount of documentation required for clinical trials?

E6(R3) emphasizes that documentation should be proportionate to the risks and the criticality of the data. This means that some documentation may be reduced for low-risk areas, but detailed documentation

Using the Evidence

Related Articles

• Clinical Research Assistant: A Day in the Life and Career Outlook
• Clinical Research Coordinator vs. Clinical Trial Coordinator: What's the Difference?
• Clinical Associates: Roles, Responsibilities, and Career Path
• Clinical Research Associate vs Clinical Research Coordinator: What's the Difference?
• Clinical Research Career Path: From Assistant to Director

References and Further Reading

• Occupational Outlook Handbook. U.S. Bureau of Labor Statistics.
• O*NET OnLine. U.S. Department of Labor.
• Office of Intramural Training and Education. National Institutes of Health.
• Careers at NSF. U.S. National Science Foundation.
• Career Services. American Society for Microbiology.
• AAVMC Career Resources. Association of American Veterinary Medical Colleges.
• NCBI Literature Resources. National Center for Biotechnology Information.
• PubMed. National Library of Medicine.

This article is educational and does not replace institutional policy, professional advice, or applicable safety and regulatory requirements.